CTX.TO - Crescita Therapeutics Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.9000
0.0000 (0.00%)
At close: 2:45PM EST
Stock chart is not supported by your current browser
Previous Close0.9000
Open0.8900
Bid0.9000 x 0
Ask0.9100 x 0
Day's Range0.8900 - 0.9300
52 Week Range0.3850 - 1.2300
Volume43,967
Avg. Volume43,788
Market Cap19M
Beta (5Y Monthly)1.64
PE Ratio (TTM)3.57
EPS (TTM)0.2520
Earnings DateAug 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Crescita Therapeutics (TSE:CTX) Using Too Much Debt?
    Simply Wall St.

    Is Crescita Therapeutics (TSE:CTX) Using Too Much Debt?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • CNW Group

    Crescita Reports 2019 Third Quarter Results

    Crescita Reports 2019 Third Quarter Results

  • CNW Group

    U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®

    LAVAL, QC , Nov. 5, 2019 /CNW Telbec/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the U.S. Food and Drug Administration ("FDA") approved the enhanced formulation of Pliaglis® (the "Enhanced Formulation") following its statutory six-month review process and in line with the target action date under the Prescription Drug User Fee Act ("PDUFA"). While the U.S. patent covering the original formulation of Pliaglis® expired on September 28 . 2019, the U.S. patent covering the Enhanced Formulation with extended protection to 2031, is in the process of being added to the Orange Book.

  • Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals
    PR Newswire

    Sundial and Crescita Sign Exclusive Partnership to Develop Cannabis and Hemp Topicals

    CALGARY and LAVAL, QC, Oct. 28, 2019 /PRNewswire/ - Sundial Growers Inc. (Nasdaq:SNDL) ("Sundial"), a Canadian licensed producer of cannabis and Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita"), a Canadian commercial dermatology company, today announced a development and licensing agreement (the "Agreement") granting Sundial the worldwide rights to Crescita's proprietary transdermal delivery technologies for the development of topicals containing cannabis and hemp. The Agreement will enable the development of unique, high-quality cannabis and hemp topicals for the Canadian and international non-prescription markets.

  • The Crescita Therapeutics (TSE:CTX) Share Price Has Gained 89% And Shareholders Are Hoping For More
    Simply Wall St.

    The Crescita Therapeutics (TSE:CTX) Share Price Has Gained 89% And Shareholders Are Hoping For More

    Crescita Therapeutics Inc. (TSE:CTX) shareholders might be concerned after seeing the share price drop 18% in the last...

  • Is Crescita Therapeutics Inc. (TSE:CTX) A High Quality Stock To Own?
    Simply Wall St.

    Is Crescita Therapeutics Inc. (TSE:CTX) A High Quality Stock To Own?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Before You Buy Crescita Therapeutics Inc. (TSE:CTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Crescita Therapeutics Inc. (TSE:CTX), Consider Its Volatility

    If you own shares in Crescita Therapeutics Inc. (TSE:CTX) then it's worth thinking about how it contributes to the...

  • PR Newswire

    Crescita Reports Profitable 2019 Second Quarter Results

    Record Revenue of $9.4 Million and Adjusted EBITDA of $5.1 Million LAVAL, QC , Aug. 8, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial ...

  • CNW Group

    United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®

    LAVAL, QC , July 16, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the United States Patent and Trademark Office ("USPTO") has granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis® which provides extended patent protection until 2031. "The newly granted U.S. patent further strengthens our intellectual property portfolio," said Serge Verreault , President and CEO of Crescita. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • PR Newswire

    Crescita Therapeutics to Host Investor Webcast on July 24, 2019

    LAVAL, QC, July 11, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it will host a webcast investor presentation on Wednesday, July 24, at 11:00 AM ET. During the webcast, Serge Verreault, Crescita's President and CEO, will provide an introduction to the Company through a PowerPoint presentation that will cover the key areas of Crescita's business, including an overview of the Company's commercial and pipeline products, patented transdermal delivery technologies, its strategy, as well as growth opportunities.

  • Could Crescita Therapeutics Inc.'s (TSE:CTX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Crescita Therapeutics Inc.'s (TSE:CTX) Investor Composition Influence The Stock Price?

    The big shareholder groups in Crescita Therapeutics Inc. (TSE:CTX) have power over the company. Generally speaking, as...

  • CNW Group

    Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy

    LAVAL, QC , July 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has received the second instalment of € $1.25 million (~CDN $1.88 million ) of the up-front payment related to the out-licensing of Pliaglis in Italy , France , Spain and Portugal , from its partner, Cantabria Labs. The 2nd instalment was received following the completion of the transition activities from Galderma to Cantabria  leading to the first commercial sale of Pliaglis in Italy by the Cantabria sales team. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • CNW Group

    Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

    LAVAL, QC , June 26, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company") announced today that the Toronto Stock Exchange (the "TSX") has approved the Company's intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. Pursuant to the NCIB notice filed with the TSX, the Company intends to acquire up to a maximum of 1,000,000 Common Shares, or approximately 6% of its public float as of June 26, 2019 for cancellation over the next 12 months.

  • CNW Group

    Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid

    LAVAL, QC , June 17, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company"), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it intends to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. The Company's normal course issuer bid, which is expected to be for up to 1,000,000 common shares, or approximately 6% of its public float, will be made in accordance with the requirements of the Toronto Stock Exchange (the "TSX") and remains subject to TSX approval.

  • PR Newswire

    Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California

    LAVAL, QC, May 30, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that its Executive Chairman, Dan Chicoine will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 3:00 p.m. pacific time. "We are very excited to be presenting at this prestigious conference and we look forward to introducing Crescita to a new list of potential U.S. investors" stated Dan Chicoine, executive chairman. The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.